Tolerability and discontinuation rates in teriflunomide-treated patients

References

1. ↵
   1. Miller AE

   (2015) Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis. Clin Ther 37, 2366–2380.
2. ↵
   1. Confavreux C,
   2. O'Connor P,
   3. Comi G,
   4. Freedman MS,
   5. Miller AE,
   6. Olsson TP,
   7. et al.

   (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13, 247–256.
3. ↵
   1. O'Connor P,
   2. Wolinsky JS,
   3. Confavreux C,
   4. Comi G,
   5. Kappos L,
   6. Olsson TP,
   7. et al.

   (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365, 1293–12303.
4. ↵
   1. Freedman MS

   (2013) Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther Adv Chronic Dis 4, 192–205.
5. ↵
   1. Oh J,
   2. O'Connor PW

   (2014) Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 7, 239–252.
6. ↵
   1. Vermersch P,
   2. Czlonkowska A,
   3. Grimaldi LM,
   4. Confavreux C,
   5. Comi G,
   6. Kappos L,
   7. et al.

   (2014) Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 20, 705–716.